CN109475514A - 使用(2r,6r)-羟基去甲氯胺酮和(2s,6s)-羟基去甲氯胺酮治疗抑郁、焦虑、快感缺乏、疲劳、自杀意念和创伤后应激障碍的方法 - Google Patents

使用(2r,6r)-羟基去甲氯胺酮和(2s,6s)-羟基去甲氯胺酮治疗抑郁、焦虑、快感缺乏、疲劳、自杀意念和创伤后应激障碍的方法 Download PDF

Info

Publication number
CN109475514A
CN109475514A CN201780029039.8A CN201780029039A CN109475514A CN 109475514 A CN109475514 A CN 109475514A CN 201780029039 A CN201780029039 A CN 201780029039A CN 109475514 A CN109475514 A CN 109475514A
Authority
CN
China
Prior art keywords
disorder
ketamine
hnk
anxiety
symptom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780029039.8A
Other languages
English (en)
Chinese (zh)
Inventor
欧文·魏纳
卡洛斯·萨拉特
鲁因·莫阿德尔
托德·古尔德
帕诺斯·萨诺斯
克雷格·托马斯
帕特里克·莫里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
US Department of Health and Human Services
Original Assignee
University of Maryland Baltimore
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Baltimore, US Department of Health and Human Services filed Critical University of Maryland Baltimore
Publication of CN109475514A publication Critical patent/CN109475514A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780029039.8A 2016-03-25 2017-03-27 使用(2r,6r)-羟基去甲氯胺酮和(2s,6s)-羟基去甲氯胺酮治疗抑郁、焦虑、快感缺乏、疲劳、自杀意念和创伤后应激障碍的方法 Pending CN109475514A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313317P 2016-03-25 2016-03-25
US62/313,317 2016-03-25
PCT/US2017/024238 WO2017165877A1 (en) 2016-03-25 2017-03-27 Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post traumatic stress disorders

Publications (1)

Publication Number Publication Date
CN109475514A true CN109475514A (zh) 2019-03-15

Family

ID=58530652

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780029039.8A Pending CN109475514A (zh) 2016-03-25 2017-03-27 使用(2r,6r)-羟基去甲氯胺酮和(2s,6s)-羟基去甲氯胺酮治疗抑郁、焦虑、快感缺乏、疲劳、自杀意念和创伤后应激障碍的方法

Country Status (7)

Country Link
US (1) US20190083420A1 (https=)
EP (1) EP3432869A1 (https=)
JP (1) JP2019512528A (https=)
CN (1) CN109475514A (https=)
AU (1) AU2017238858A1 (https=)
CA (1) CA3019012A1 (https=)
WO (1) WO2017165877A1 (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311801A (zh) * 2016-03-25 2019-02-05 美国政府健康及人类服务部 (2r,6r)-羟基去甲氯胺酮和(2s,6s)-羟基去甲氯胺酮的晶型和合成方法
WO2020237748A1 (zh) * 2019-05-24 2020-12-03 北京大学深圳研究生院 一种长效化合物的制备方法
CN112516130A (zh) * 2020-08-31 2021-03-19 深圳瑞健生物科技有限公司 一种长效低成瘾性化合物在制备药物中的应用
CN112521357A (zh) * 2020-08-31 2021-03-19 深圳瑞健生物科技有限公司 一种长效低成瘾性hnk衍生物及其制备方法
CN113125586A (zh) * 2019-12-31 2021-07-16 成都百裕制药股份有限公司 一种1-[2-(2,4-二甲基-苯硫基)-苯基]哌嗪及其异构体的检测方法
CN114524737A (zh) * 2020-11-23 2022-05-24 江苏恒瑞医药股份有限公司 一种取代的环己酮类化合物
CN114947839A (zh) * 2022-05-27 2022-08-30 华东师范大学 大脑调控的训练方法、装置及电子设备
CN120736994A (zh) * 2025-01-26 2025-10-03 上海东西智荟生物医药有限公司 氯胺酮衍生物及其在精神疾病的治疗中的用途
US12466785B2 (en) 2020-08-31 2025-11-11 Shenzhen Ruijian Biotechnology Co., Ltd Long-acting low-addiction HNK derivative and preparation method therefor
US12486242B2 (en) 2020-08-31 2025-12-02 Shenzhen Ruijian Biotechnology Co., Ltd. Long-acting low-addiction HNK derivative and preparation method therefor

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3043785T1 (sl) 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
WO2017180589A1 (en) * 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
ES2991544T3 (es) * 2016-11-30 2024-12-04 Wolfson Philip E Ketamina para el tratamiento de síntomas relacionados con la menstruación
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
JP7548669B2 (ja) 2018-02-15 2024-09-10 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN110343050B (zh) * 2018-04-04 2021-09-24 上海键合医药科技有限公司 芳香类化合物及其制备方法和用途
AU2019262197B2 (en) 2018-05-04 2024-12-19 Perception Neuroscience, Inc. Methods of treating substance abuse
BR112022005579A2 (pt) * 2019-11-05 2022-06-21 Claes Thulin 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1,2,4-triazol-3-il]piridina para uso na prevenção e/ou no tratamento de surmenage em um mamífero

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014020155A1 (en) * 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
CN104395283A (zh) * 2011-10-14 2015-03-04 美国政府健康及人类服务部 (2r,6r)-羟基去甲氯胺酮、(s)-脱氢去甲氯胺酮以及(r,s)-氯胺酮的其他立体异构脱氢和羟基化代谢物在治疗忧郁症和神经性疼痛中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104395283A (zh) * 2011-10-14 2015-03-04 美国政府健康及人类服务部 (2r,6r)-羟基去甲氯胺酮、(s)-脱氢去甲氯胺酮以及(r,s)-氯胺酮的其他立体异构脱氢和羟基化代谢物在治疗忧郁症和神经性疼痛中的应用
WO2014020155A1 (en) * 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12473251B2 (en) 2016-03-25 2025-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine
CN109311801A (zh) * 2016-03-25 2019-02-05 美国政府健康及人类服务部 (2r,6r)-羟基去甲氯胺酮和(2s,6s)-羟基去甲氯胺酮的晶型和合成方法
US11613514B2 (en) 2016-03-25 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine
WO2020237748A1 (zh) * 2019-05-24 2020-12-03 北京大学深圳研究生院 一种长效化合物的制备方法
CN113125586B (zh) * 2019-12-31 2022-05-24 成都百裕制药股份有限公司 一种1-[2-(2，4-二甲基-苯硫基)-苯基]哌嗪及其异构体的检测方法
CN113125586A (zh) * 2019-12-31 2021-07-16 成都百裕制药股份有限公司 一种1-[2-(2,4-二甲基-苯硫基)-苯基]哌嗪及其异构体的检测方法
US12466785B2 (en) 2020-08-31 2025-11-11 Shenzhen Ruijian Biotechnology Co., Ltd Long-acting low-addiction HNK derivative and preparation method therefor
CN112516130B (zh) * 2020-08-31 2022-01-04 深圳瑞健生物科技有限公司 一种长效低成瘾性化合物在制备药物中的应用
CN112521357B (zh) * 2020-08-31 2021-10-08 深圳瑞健生物科技有限公司 一种长效低成瘾性hnk衍生物及其制备方法
CN112521357A (zh) * 2020-08-31 2021-03-19 深圳瑞健生物科技有限公司 一种长效低成瘾性hnk衍生物及其制备方法
CN112516130A (zh) * 2020-08-31 2021-03-19 深圳瑞健生物科技有限公司 一种长效低成瘾性化合物在制备药物中的应用
US12486242B2 (en) 2020-08-31 2025-12-02 Shenzhen Ruijian Biotechnology Co., Ltd. Long-acting low-addiction HNK derivative and preparation method therefor
CN114524737A (zh) * 2020-11-23 2022-05-24 江苏恒瑞医药股份有限公司 一种取代的环己酮类化合物
CN114947839A (zh) * 2022-05-27 2022-08-30 华东师范大学 大脑调控的训练方法、装置及电子设备
CN120736994A (zh) * 2025-01-26 2025-10-03 上海东西智荟生物医药有限公司 氯胺酮衍生物及其在精神疾病的治疗中的用途
CN120736994B (zh) * 2025-01-26 2025-11-18 上海东西智荟生物医药有限公司 氯胺酮衍生物及其在精神疾病的治疗中的用途

Also Published As

Publication number Publication date
WO2017165877A1 (en) 2017-09-28
EP3432869A1 (en) 2019-01-30
JP2019512528A (ja) 2019-05-16
US20190083420A1 (en) 2019-03-21
AU2017238858A1 (en) 2018-10-18
CA3019012A1 (en) 2017-09-28
WO2017165877A8 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
CN109475514A (zh) 使用(2r,6r)-羟基去甲氯胺酮和(2s,6s)-羟基去甲氯胺酮治疗抑郁、焦虑、快感缺乏、疲劳、自杀意念和创伤后应激障碍的方法
JP2022529353A (ja) 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
CN106068256B (zh) 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
CN112930175A (zh) 治疗癫痫的方法
JP2014523857A (ja) ヒストンデアセチラーゼ阻害剤
EP2510949A1 (en) Therapeutic agent for fibromyalgia
JP2018521034A (ja) ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US20070225278A1 (en) Methods for treating cognitive and other disorders
US20240207265A1 (en) TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
EP4077333A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2023081895A1 (en) Isotopically enriched analogs of 5,6-methylenedioxy-2-aminoindane (mdai)
JP2025501411A (ja) 重水素化有機化合物およびその使用
JP2025501410A (ja) 重水素化有機化合物およびその使用
US12343326B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12295937B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
WO2024254190A2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
AU2024284688A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
EP1791806A2 (en) Amine compounds and inhibiting neurotransmitter reuptake
HK40045266A (en) Method for treating epilepsy
US20070225334A1 (en) Methods for treating cognitive and other disorders
HK40046882A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40081455A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230171B (zh) 用於治疗认知损害的苯并二氮杂卓衍生物、组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190315

RJ01 Rejection of invention patent application after publication